Clascoterone and Hair Loss: A New-Generation Topical Treatment Hope

In recent years, alongside classical treatments for hair loss (such as minoxidil and finasteride), intensive research has been conducted on new molecules. One of these molecules, clascoterone, is a promising next-generation topical (applied to the skin) treatment candidate, particularly for male pattern hair loss (androgenetic alopecia).

The status of clascoterone for hair loss

Clascoterone is currently approved by the FDA only for the treatment of acne in a 1% cream formulation. However, a higher-concentration (5%) solution developed for hair loss is still in the clinical research phase. This indication has not yet received official approval, but its efficacy and safety are being evaluated through large and well-designed clinical studies.

How does it work in hair loss?

The main mechanism of male pattern hair loss is the binding of the hormone DHT (dihydrotestosterone), derived from testosterone, to androgen receptors in hair follicles, which over time leads to follicle miniaturization. This process causes hair thinning and eventually hair loss.

The mechanism of action of clascoterone is as follows:

• It binds to androgen receptors, preventing DHT from attaching to these receptors.
• Thus, the damaging effect of DHT on hair follicles is locally blocked.
• Its effect is mainly limited to the area where it is applied, with a very low risk of systemic (body-wide) hormonal changes.
• In this respect, it differs from orally taken drugs such as finasteride; while finasteride reduces DHT levels throughout the body, clascoterone suppresses DHT signaling only in the treated area.

What do clinical data show?

According to the results of Phase 3 clinical trials (SCALP-1 and SCALP-2) reported in current research, clascoterone 5% solution, compared to placebo:

• Provided a significant increase in hair density.
• Showed a notable increase in adjusted hair count in certain patient groups.

However, until all data from these studies are published and long-term results become clear, it is not yet certain whether the product will receive official approval or what its true clinical success rate will be.

Who is it promising for, and who is it not?

Clascoterone should not be regarded as a “miracle” solution that completely reverses hair loss. In particular:

• In individuals with complete hair loss where hair follicles are no longer present, this treatment will not be able to restore hair.
• However, in individuals whose scalp has not completely thinned and who still have thinning hair or ongoing hair loss, it may be a promising option to slow down hair loss and preserve existing hair.

Conclusion

Clascoterone offers a new mechanism that could serve as an alternative to long-standing approaches in the treatment of hair loss. Its localized action and low risk of systemic side effects make it an attractive candidate, especially for patients concerned about hormonal side effects.

Although it is not yet an approved hair loss medication, if ongoing clinical trials yield positive results, it may play an important role in the future treatment of androgenetic alopecia. For now, clascoterone is not a solution that fully restores hair; rather, it is a scientifically promising new approach to slow down hair loss and protect existing hair.